SCHEMBL6739617

SCHEMBL6739617

Nc1csnc1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.42
MAPT P10636 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
KDM4E B2RXH2 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
LMNA P02545 2/20 0.42
HPGD P15428 2/20 0.42
GLA P06280 1/20 0.42
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
ADORA2A P29274 5/20 0.41
ADORA1 P30542 4/20 0.41
ADORA3 P0DMS8 2/20 0.39
ADORA2B P29275 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
NPC1 O15118 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11107027 0.79 CYP2A6 (0.48) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL4587159 0.76 CYP11B1 (0.42) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL28020956 0.74 CYP11B1 (0.41) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL27862904 0.74 ALDH1A1 (0.42) ALDH1A1CYP1A2KDM4ESMN1; SMN2LMNA
SCHEMBL27304439 0.74 CYP11B1 (0.41) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL28013350 0.74 CYP11B1 (0.41) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL28957794 0.74 CYP11B1 (0.41) ALDH1A1MAPTCYP1A2CYP2D6CYP2C19
SCHEMBL11431701 0.71 BCAT2 (0.47) ALDH1A1KDM4ENPC1RAB9AGAA
SCHEMBL5154806 0.69 LMNA (0.45) ALDH1A1MAPTKDM4ESMN1; SMN2LMNA
SCHEMBL11550969 0.69 ALDH1A1 (0.43) ALDH1A1KDM4ESMN1; SMN2LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641852-B Sulfonamides as GPR 40-and GPR 120-agonists 东佩制药股份公司 2022-08-26 CN disclosed
EP-3497085-B1 SULFONAMIDES AS GPR40- AND GPR120-AGONISTS DOMPE FARM SPA (IT) 2020-07-22 EP disclosed
EP-3497085-A1 SULFONAMIDES AS GPR40- AND GPR120-AGONISTS Dompé farmaceutici S.p.A. (IT) 2019-06-19 EP disclosed
US-20190169142-A1 SULFONAMIDES AS GPR40- AND GPR120-AGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2019-06-06 US disclosed
CN-109641852-A Sulfonamides as GPR 40-and GPR 120-agonists 东佩制药股份公司 2019-04-16 CN disclosed
WO-2018029150-A1 SULFONAMIDES AS GPR40- AND GPR120-AGONISTS DOMPE' FARMACEUTICI S.P.A. (IT) 2018-02-15 WO disclosed
EP-3281937-A1 SULFONAMIDES AS GPR40- AND GPR120-AGONISTS Dompé farmaceutici S.p.A. (IT) 2018-02-14 EP disclosed
US-20040023807-A1 3-Arylisothiazoles and their use as herbicides BASF AKTIENGESELLSCHAFT (DE) 2004-02-05 US disclosed
EP-1289970-A1 3-ARYLISOTHIAZOLES AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 2003-03-12 EP disclosed
WO-2001087863-A1 3-ARYLISOTHIAZOLES AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023807-A1 3-Arylisothiazoles and their use as herbicides DDT, HAX1, SULT1E1 ALDH1A1 142/4885MAPT 2566/4885CYP1A2 90/4885
US-20190169142-A1 SULFONAMIDES AS GPR40- AND GPR120-AGONISTS GPR119, GPR88, GPR84 ALDH1A1 3932/4885MAPT 4139/4885CYP1A2 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.